Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for taming involuntary movements

NCT ID NCT03176771

Symptom relief Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a once-daily drug called MT-5199 in 256 adults with tardive dyskinesia, a condition causing uncontrollable movements. The goal was to see if the drug could reduce these movements safely. Participants had mental health conditions like schizophrenia or bipolar disorder and had moderate to severe movement issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

256 people

The number who actually took part.

Started

Jun 2017

Finished

Sep 2020

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have one of the following clinical diagnoses for at least 3 months prior to screening: Schizophrenia or Schizoaffective Disorder, Bipolar Disorder, or Depressive Disorders. * Have a clinical diagnosis of neuroleptic-induced TD. * Have moderate or severe TD. * If using maintenance medication(s) for schizophrenia or schizoaffective disorder, or bipolar disorder, or depressive disorders, be on stable doses. Exclusion Criteria: * Have an active, clinically significant unstable medical condition in screening period. * Have a significant risk of suicidal or violent behavior. * Have a known history of long QT syndrome or cardiac tachy-arrhythmia. * Are currently pregnant or breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tardive dyskinesia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

tardive dyskinesia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tardive dyskinesia

Contacts and locations

Locations

  • Abe Clinic

    Tokyo, Japan

  • Aichi Psychiatric Medical Center

    Aichi, Japan

  • Akari Clinic

    Okinawa, Japan

  • Akita City Hospital

    Akita, Japan

  • Akita University Hospital

    Akita, Japan

  • Arakaki Hospital

    Okinawa, Japan

  • Awazu Neuropsychiatric Sanatorium

    Ishikawa, Japan

  • Chikusuikai Hospital

    Fukuoka, Japan

  • Fujimidai Hospital

    Kanagawa, Japan

  • Fukuoka University Hospital

    Fukuoka, Japan

  • General incorporated association Shinkoukai Shinkouen

    Ehime, Japan

  • Hatano Kosei Hospital

    Kanagawa, Japan

  • Hayakawa Clinic

    Hiroshima, Japan

  • Hayashishita Hospital

    Hokkaido, Japan

  • Hino Hospital

    Kanagawa, Japan

  • Hirosaki Aiseikai Hospital

    Aomori, Japan

  • Hirota Clinic

    Fukuoka, Japan

  • Hizen Psychiatric Center

    Saga, Japan

  • Hoaki Hospital

    Ōita, Japan

  • Holy Cross Hospital

    Gifu, Japan

  • Hotei Hospital

    Aichi, Japan

  • Hozumi Clinic

    Tokyo, Japan

  • Hyogo prefecture - Hyogo Mental Health Center

    Hyōgo, Japan

  • Iizukakinen Hospital

    Fukuoka, Japan

  • Ishikane Hospital

    Hokkaido, Japan

  • Ishiki Hospital

    Kagoshima, Japan

  • Kamo Psychiatric Center

    Hiroshima, Japan

  • Kawada Hospital

    Toyama, Japan

  • Keihan Hospital

    Osaka, Japan

  • Kishiro Mental Clinic

    Kanagawa, Japan

  • Kitaodawara Hospital Meihoukai Medical Corporation Association

    Kanagawa, Japan

  • Kobe University Hospital

    Hyōgo, Japan

  • Kohnodai Hospital , National Center for Global Health and Medicine

    Chiba, Japan

  • Kuramitsu Hospital

    Fukuoka, Japan

  • Kyorin University Hospital

    Tokyo, Japan

  • Kyowakai Healthcare Corpration Hannan Hospital

    Osaka, Japan

  • Maynds Tower Mental Clinic

    Tokyo, Japan

  • Medical corporation KOSEIKAI KUSATSU HOSPITAL

    Hiroshima, Japan

  • Medical corporation Shouhokai Toda Internal Medicine and Rehabilitation Department

    Hyōgo, Japan

  • Mihara Hospital

    Hiroshima, Japan

  • Mikawa Hospital

    Aichi, Japan

  • Minami Kyushu Sakura Hospital

    Kagoshima, Japan

  • Minamigaoka Hospital

    Fukuoka, Japan

  • Minamitoyama Nakagawa Hospital

    Toyama, Japan

  • Minato Hospital

    Aomori, Japan

  • Miyagi Psychiatric Center

    Miyagi, Japan

  • Nanko Kokorono Clinic

    Fukushima, Japan

  • Nara Medical University Hospital

    Nara, Japan

  • National Center of Neurology and Psychiatry

    Tokyo, Japan

  • National Hospital Organization Hokkaido Medical Center

    Hokkaido, Japan

  • National Hospital Organization Kanmon Medical Center

    Yamaguchi, Japan

  • National Hospital Organization Komoro kogen Hospital

    Nagano, Japan

  • National Hospital Organization Shimofusa Psychiatric Medical Center

    Chiba, Japan

  • Nishigahara Hospital

    Tokyo, Japan

  • North Alps Medical Center Azumi Hospital

    Nagano, Japan

  • Numazu Chuo Hospital

    Shizuoka, Japan

  • Obihiro-Kosei General Hospital

    Hokkaido, Japan

  • Okehazama Hospital Fujita Kokoro Care Center

    Aichi, Japan

  • Ongata Hospital

    Tokyo, Japan

  • Public Okitama General Hospital

    Yamagata, Japan

  • Rainbow & Sea Hospital

    Saga, Japan

  • Sagaarashiyama Tanaka Clinic

    Kyoto, Japan

  • Samariya Hospital

    Okinawa, Japan

  • Sangenjaya Neurology-Psychosomatic Clinic

    Tokyo, Japan

  • Sanwa Central Hospital

    Nagasaki, Japan

  • Sapporo City General Hospital

    Hokkaido, Japan

  • Seimou Hospital

    Gunma, Japan

  • Seinan Hospital

    Aomori, Japan

  • Senzoku Mental Clinic

    Tokyo, Japan

  • Shiga University of Medical Science Hospital

    Shiga, Japan

  • Shimane University Hospital

    Shimane, Japan

  • Shiunkai Yokohama Hospital

    Kanagawa, Japan

  • Sho Midori Hospital

    Saitama, Japan

  • Soushu Hospital

    Kanagawa, Japan

  • Syonan Hospital

    Nagano, Japan

  • Takeda General Hospital

    Fukushima, Japan

  • Taniyama Hospital

    Kagoshima, Japan

  • Teine Hospital

    Hokkaido, Japan

  • Yahata Kousei Hospital

    Fukuoka, Japan

  • Yasuda Hospital

    Miyagi, Japan

  • Yatsushirokosei Hospital

    Kumamoto, Japan

  • Yuge Hospital

    Kumamoto, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.